Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Product Type
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

NCT-02 is a degrader of cyclin K.1 It reduces the levels of cyclin K in patient-derived colorectal cancer (CRC) cells in a concentration-dependent manner. NCT-02 inhibits cancer cell proliferation in CRC tissue samples isolated from the colon (IC50s = 0.9-20.6 µM), as well as from hepatic, lung, and rectal metastases (IC50s = 0.5-11.8, 1, and 1.4-38.4 µM, respectively). It decreases the levels of Ataxia-telangiectasia mutated kinase (ATM) and RAD51 in patient-derived CRC tissues when used at concentrations 0.7 and 0.5 µM, respectively. NCT-02 (3 µM) reduces the number of spheroids formed and induces poly(ADP-ribose) polymerase (PARP) cleavage in patient-derived CRC spheroid cultures.
WARNING This product is not for human or veterinary use.
1. Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer. Cell Rep. 36(3), 109394 (2021).